EUCTR2009-017978-21-PTActive, not recruitingPhase 1
Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE) - PREMIERE Registry
Merck Serono S.A. - Geneva0 sites1,148 target enrollmentStarted: August 11, 2011Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 1,148
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •The registry target population includes all subjects who participated in Sponsor oral cladribine phase I to III clinical trials in MS associated with a protocol approved prior to the time of submission of the marketing application and completed (last patient, last visit) after November 2008.
- •All subjects in the target population described in section 5.1 will be eligible for enrollment in the registry once their participation in the clinical trial has ended. The following inclusion criteria must be fulfilled:
- •Prior enrollment into selected clinical trials, regardless of randomization to either IMP or placebo, once participation in the clinical trial or in the clinical trial extension has ended
- •Written informed consent is given.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2175
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
Exclusion Criteria
- •The following reasons will exclude subjects from registry participation:
- •Subjects who cannot be reached by phone;
- •Subjects who are unable to answer the registry questionnaires and who do not have a next of kin or caregiver available to answer the registry questionnaires;
- •Subjects who – either during the lag interval or subsequently – enter an interventional study.
Investigators
Similar Trials
Active, not recruiting
Phase 1
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trialsEUCTR2009-017978-21-GBMerck Serono S.A. - Geneva1,148
Active, not recruiting
Phase 1
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trialsEUCTR2009-017978-21-BEMerck Serono S.A. - Geneva1,148
Active, not recruiting
Phase 1
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trialsEUCTR2009-017978-21-LVMerck Serono S.A. - Geneva2,175
Active, not recruiting
Phase 1
ong-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trialsEUCTR2009-017978-21-FIMerck Serono S.A. - Geneva2,175
Active, not recruiting
Phase 1
Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE) - PREMIERE RegistryMultiple Sclerosis patients who have participated in cladribine tablets clinical trialsMedDRA version: 17.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-017978-21-PLMerck Serono S.A. - Geneva1,148